915192-34-6

Basic information

• Product Name: 1-(2,6-dimethoxyphenyl)Cyclopropanecarboxylic acid
• Synonyms: 1-(2,6-dimethoxyphenyl)Cyclopropanecarboxylic acid;1-(2,6-dimethoxyphenyl)cyclopropane-1-carboxylicacid
• CAS NO: 915192-34-6
• Molecular Formula: C₁₂H₁₄O₄
• Molecular Weight: 222.23716
• Mol File: 915192-34-6.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-(2,6-dimethoxyphenyl)Cyclopropanecarboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(2,6-dimethoxyphenyl)Cyclopropanecarboxylic acid(915192-34-6)
• EPA Substance Registry System: 1-(2,6-dimethoxyphenyl)Cyclopropanecarboxylic acid(915192-34-6)

Safety Data

• Hazardous Substances Data: 915192-34-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
1-(2,6-dimethoxyphenyl)Cyclopropanecarboxylic acid is utilized as a building block in the synthesis of pharmaceuticals and other organic compounds. Its unique structure allows for the creation of a wide range of molecules with potential therapeutic properties.
Used in Coordination Chemistry:
In coordination chemistry, 1-(2,6-dimethoxyphenyl)Cyclopropanecarboxylic acid can act as a ligand, forming complexes with metal ions. This application is crucial for studying the properties and reactivity of metal complexes, which can lead to the development of new catalysts and materials.
Used in Material Development:
1-(2,6-dimethoxyphenyl)Cyclopropanecarboxylic acid may have potential applications in the development of new materials due to its unique structural features and ability to interact with other molecules. This could lead to the creation of advanced materials with specific properties for various industries, such as electronics, aerospace, or automotive.

Upstream product

• 16932-45-9 1-bromo-2,6-dimethoxybenzene 
• 1185886-64-9 methyl 1-(2-methoxy-6-methylphenyl)cyclopropanecarboxylate 
• 915192-33-5 ethyl 1-(2,6-dimethoxyphenyl)cyclopropanecarboxylate 
• 915192-32-4 ethyl 2-(2,6-dimethoxyphenyl)acrylate 

Relevant articles and documents

Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use

The invention discloses compounds of Formula (I), wherein A1, R1, R2, R3, R4, and n are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.

Remote electronic control in the regioselective reduction of succinimides: A practical, scalable synthesis of EP4 antagonist MF-310

(Chemical Equation Presented) A practical large-scale chromatography-free synthesis of EP4 antagonist MF-310, a potential new treatment for chronic inflammation, is presented. The synthetic route provided MF-310 as its sodium salt in 10 steps and 17% overall yield from commercially available pyridine dicarboxylate 7. The key features of this sequence include a unique regioselective reduction of succinimide 2 controlled by the electronic properties of a remote pyridine ring, preparation of cyclopropane carboxylic acid 3 via a Corey - Chaykovsky cyclopropanation, and a short synthesis of sulfonamide 5. 2009 American Chemical Society.

QUINOLINE DERIVATIVES AS EP4 ANTAGONISTS

The invention is directed to quinoline derivatives as prostaglandin E type receptor antagonists useful for the treatment of EP4 mediated diseases or conditions, such as acute and chronic pain, osteoarthritis, rheumatoid arthritis and cancer. The derivatives have the following structure of formula (I): wherein A and B represents either a nitrogen atom or a CH group with the proviso that they cannot both simultaneously be CH, Q can represent a nitrogen or a carbon atom, and Y and Z are either a nitrogen atom., a N(O) group or a C(R5) group. Pharmaceutical compositions comprising the derivatives of formula (I) are also included.